CRISPR/Cas9-mediated Foxp1 silencing restores immune surveillance in an immunocompetent A20 lymphoma model
The interaction of lymphoma cells with their microenvironment has an important role in disease pathogenesis and is being actively pursued therapeutically using immunomodulatory drugs, including immune checkpoint inhibitors. Diffuse large B-cell lymphoma (DLBCL) is an aggressive high-grade disease th...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Frontiers Media
2020
|
| _version_ | 1797107159776886784 |
|---|---|
| author | Felce, SL Anderson, A Maguire, S Gascoyne, D Armstrong, R Wong, KK Li, D Banham, A |
| author_facet | Felce, SL Anderson, A Maguire, S Gascoyne, D Armstrong, R Wong, KK Li, D Banham, A |
| author_sort | Felce, SL |
| collection | OXFORD |
| description | The interaction of lymphoma cells with their microenvironment has an important role in disease pathogenesis and is being actively pursued therapeutically using immunomodulatory drugs, including immune checkpoint inhibitors. Diffuse large B-cell lymphoma (DLBCL) is an aggressive high-grade disease that remains incurable in ~40% of patients treated with R-CHOP immunochemotherapy. The FOXP1 transcription factor is abundantly expressed in such high-risk DLBCL and we recently identified its regulation of immune response signatures, in particular, its suppression of the cell surface expression of major histocompatibility class II (MHC-II), which has a critical role in antigen presentation to T cells. Using CRISPR/Cas9 genome editing we have depleted Foxp1 expression in the aggressive murine A20 lymphoma cell line. When grown in BALB/c mice, this cell line provides a high-fidelity immunocompetent disseminated lymphoma model that displays many characteristics of human DLBCL. Transient Foxp1-depletion using siRNA, and stable depletion using CRISPR (generated by independently targeting Foxp1 exon six or seven) upregulated cell surface I-Ab (MHC-II) expression without impairing cell viability in vitro. RNA sequencing of Foxp1-depleted A20 clones identified commonly deregulated genes, such as the B-cell marker Cd19, and hallmark DLBCL signatures such as MYC-targets and oxidative phosphorylation. Immunocompetent animals bearing Foxp1-depleted A20 lymphomas showed significantly-improved survival, and 20% did not develop tumors; consistent with modulating immune surveillance, this was not observed in immunodeficient NOD SCIDγ mice. The A20 Foxp1 CRISPR model will help to further characterize the contribution of Foxp1 to lymphoma immune evasion and the potential for Foxp1 targeting to synergize with other immunotherapies. |
| first_indexed | 2024-03-07T07:12:05Z |
| format | Journal article |
| id | oxford-uuid:4667e2a2-fa4b-4389-8dc7-41c9cfade6f7 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T07:12:05Z |
| publishDate | 2020 |
| publisher | Frontiers Media |
| record_format | dspace |
| spelling | oxford-uuid:4667e2a2-fa4b-4389-8dc7-41c9cfade6f72022-07-06T10:12:31ZCRISPR/Cas9-mediated Foxp1 silencing restores immune surveillance in an immunocompetent A20 lymphoma modelJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:4667e2a2-fa4b-4389-8dc7-41c9cfade6f7EnglishSymplectic ElementsFrontiers Media2020Felce, SLAnderson, AMaguire, SGascoyne, DArmstrong, RWong, KKLi, DBanham, AThe interaction of lymphoma cells with their microenvironment has an important role in disease pathogenesis and is being actively pursued therapeutically using immunomodulatory drugs, including immune checkpoint inhibitors. Diffuse large B-cell lymphoma (DLBCL) is an aggressive high-grade disease that remains incurable in ~40% of patients treated with R-CHOP immunochemotherapy. The FOXP1 transcription factor is abundantly expressed in such high-risk DLBCL and we recently identified its regulation of immune response signatures, in particular, its suppression of the cell surface expression of major histocompatibility class II (MHC-II), which has a critical role in antigen presentation to T cells. Using CRISPR/Cas9 genome editing we have depleted Foxp1 expression in the aggressive murine A20 lymphoma cell line. When grown in BALB/c mice, this cell line provides a high-fidelity immunocompetent disseminated lymphoma model that displays many characteristics of human DLBCL. Transient Foxp1-depletion using siRNA, and stable depletion using CRISPR (generated by independently targeting Foxp1 exon six or seven) upregulated cell surface I-Ab (MHC-II) expression without impairing cell viability in vitro. RNA sequencing of Foxp1-depleted A20 clones identified commonly deregulated genes, such as the B-cell marker Cd19, and hallmark DLBCL signatures such as MYC-targets and oxidative phosphorylation. Immunocompetent animals bearing Foxp1-depleted A20 lymphomas showed significantly-improved survival, and 20% did not develop tumors; consistent with modulating immune surveillance, this was not observed in immunodeficient NOD SCIDγ mice. The A20 Foxp1 CRISPR model will help to further characterize the contribution of Foxp1 to lymphoma immune evasion and the potential for Foxp1 targeting to synergize with other immunotherapies. |
| spellingShingle | Felce, SL Anderson, A Maguire, S Gascoyne, D Armstrong, R Wong, KK Li, D Banham, A CRISPR/Cas9-mediated Foxp1 silencing restores immune surveillance in an immunocompetent A20 lymphoma model |
| title | CRISPR/Cas9-mediated Foxp1 silencing restores immune surveillance in an immunocompetent A20 lymphoma model |
| title_full | CRISPR/Cas9-mediated Foxp1 silencing restores immune surveillance in an immunocompetent A20 lymphoma model |
| title_fullStr | CRISPR/Cas9-mediated Foxp1 silencing restores immune surveillance in an immunocompetent A20 lymphoma model |
| title_full_unstemmed | CRISPR/Cas9-mediated Foxp1 silencing restores immune surveillance in an immunocompetent A20 lymphoma model |
| title_short | CRISPR/Cas9-mediated Foxp1 silencing restores immune surveillance in an immunocompetent A20 lymphoma model |
| title_sort | crispr cas9 mediated foxp1 silencing restores immune surveillance in an immunocompetent a20 lymphoma model |
| work_keys_str_mv | AT felcesl crisprcas9mediatedfoxp1silencingrestoresimmunesurveillanceinanimmunocompetenta20lymphomamodel AT andersona crisprcas9mediatedfoxp1silencingrestoresimmunesurveillanceinanimmunocompetenta20lymphomamodel AT maguires crisprcas9mediatedfoxp1silencingrestoresimmunesurveillanceinanimmunocompetenta20lymphomamodel AT gascoyned crisprcas9mediatedfoxp1silencingrestoresimmunesurveillanceinanimmunocompetenta20lymphomamodel AT armstrongr crisprcas9mediatedfoxp1silencingrestoresimmunesurveillanceinanimmunocompetenta20lymphomamodel AT wongkk crisprcas9mediatedfoxp1silencingrestoresimmunesurveillanceinanimmunocompetenta20lymphomamodel AT lid crisprcas9mediatedfoxp1silencingrestoresimmunesurveillanceinanimmunocompetenta20lymphomamodel AT banhama crisprcas9mediatedfoxp1silencingrestoresimmunesurveillanceinanimmunocompetenta20lymphomamodel |